Analysis Astellas Pharma, Inc. (ALPMF)
6/1/2024
Analysis of Astellas Pharma, Inc. (ALPMF)
Astellas Pharma, Inc. is a pharmaceutical company based in Japan. The company is known for its focus on innovative research and development in the healthcare sector. Astellas Pharma has a strong presence in the global pharmaceutical market, with a diverse portfolio of products that cover a wide range of therapeutic areas.In terms of financial performance, Astellas Pharma has shown steady growth over the years, with consistent revenue and profit margins. The company's strong research and development pipeline, along with strategic partnerships and acquisitions, have contributed to its success in the industry.
From a stock market perspective, Astellas Pharma's stock has shown resilience and stability, reflecting investor confidence in the company's long-term growth prospects. The company's solid fundamentals and commitment to innovation make it an attractive investment option for those looking to invest in the pharmaceutical sector.
Overall, Astellas Pharma, Inc. appears to be a well-established and reputable company with a promising future in the pharmaceutical industry.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided yet. The previous results, ending on February 27, 2025, were handled by the Transfer Agent. The results before that, ending on January 31, 2025, were released after hours. The results for October 31, 2024, were not provided at a specific time. The results for August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow. The balance sheet shows a positive current ratio, but a relatively high total debt to equity ratio. The profit margin and operating margin are both healthy, indicating efficient operations. The company's fiscal year ends in September 2023, with notable figures such as revenue, EBITDA, and net income.
Moving on to stock statistics, key metrics such as short ratio, float shares, and shares outstanding are provided. The percentage held by insiders and institutions, as well as short interest, give insights into investor sentiment.
Valuation metrics show metrics like P/E ratios, price to book, and price to sales ratios. The market capitalization and enterprise value provide an overview of the company's total value in the market.
Stock price summary includes data on beta, moving averages, and the company's 52-week price range and change.
Lastly, dividends and splits information details dividend rates, payout ratios, and historical split data, providing insights for investors interested in the company's dividend policy.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, suggesting efficient cost control measures.
4. Earnings before interest and taxes (EBIT) have shown an upward trend, reaching $117.7 billion in 2023 from $69.9 billion in 2020.
5. Net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023.
6. The company has been able to maintain a healthy EBITDA margin over the years, indicating strong operational performance.
7. Diluted earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
8. The company's effective tax rate has remained relatively stable, allowing for consistent net income growth.
9. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving over the years.
Balance Sheet
These are balance sheets. Here are the conclusions based on the provided data:1. The total assets have been increasing over the years, reaching the highest value in 2023 at $352,583,000,000.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2023 at $209,017,000,000.
4. Total liabilities have also been increasing, reaching the highest value in 2023 at $290,437,000,000.
5. Shareholders' equity has been fluctuating, with the highest value in 2020 at $65,339,000,000.
6. The company has been relying more on non-current assets to support its operations over the years.
7. There is a significant amount of debt in the company's capital structure, both short-term and long-term.
8. The company has been investing heavily in investments and advances as part of its non-current assets.
9. Retained earnings have been negative in some years, indicating losses or dividend payouts exceeding profits.
10. The company has been maintaining a significant amount of cash and cash equivalents over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing, indicating improved operational efficiency.
3. Financing activities show significant fluctuations, especially in terms of common stock repurchase and long-term debt issuance.
4. Investing activities also vary, with notable amounts spent on the sale and purchase of investments.
5. The end cash position has been fluctuating, but overall, it has shown a positive trend.
6. Interest paid has increased over the years, which could indicate higher debt levels.
7. Income tax paid has also fluctuated, but it seems to be correlated with the company's profitability.
8. Stock-based compensation has been a significant factor in the company's cash flow statement.
9. The company has been actively managing its cash flow through various activities like dividends, debt payments, and investments.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share (EPS), we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This represents an increase from the EPS of $1.17 reported a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This is higher than the EPS of $1.35 reported in the same quarter last year.
3. For the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This shows growth from the EPS of $5.67 reported in the previous fiscal year.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This indicates a potential increase from the EPS of $6.10 expected for the current fiscal year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The growth rate for the current quarter is estimated to be 5.1%.
2. Next Quarter: The growth rate for the next quarter is estimated to be 5.2%.
3. Current Year: The growth rate for the current year is estimated to be 7.6%.
4. Next Year: The growth rate for the next year is estimated to be 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is estimated to be 20.1%.
6. Next 5 Years (per annum): The average annual growth rate for the next 5 years is estimated to be 9.7%.
These estimates suggest a positive growth trend for the company, with a slight decrease in growth rate compared to the past 5 years but still showing healthy growth prospects for the future.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.MACD of ALPMF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
